amantadine has been researched along with Parkinson Disease, Secondary in 62 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The administration of diuretics to a 64 year old patient with Parkinsonian disease treated by amantadine, orphenadrine and Modopart and presenting an oedemia of the legs, induced the apparition of myoclonic jerks similar to those observed in a bismuth intoxication." | 7.66 | [Edemas and myocloni concerning a patient with Parkinson's disease treated by amantadine (author's transl)]. ( Brion, S; Chevalier, JF; Renier, E, 1980) |
| "The administration of diuretics to a 64 year old patient with Parkinsonian disease treated by amantadine, orphenadrine and Modopart and presenting an oedemia of the legs, induced the apparition of myoclonic jerks similar to those observed in a bismuth intoxication." | 3.66 | [Edemas and myocloni concerning a patient with Parkinson's disease treated by amantadine (author's transl)]. ( Brion, S; Chevalier, JF; Renier, E, 1980) |
| "Amantadine and biperiden were equally effective in relieving neuroleptic-induced EPS and did not exacerbate TD-type movements." | 2.68 | No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients. ( Geraisy, N; Schwartz, M; Silver, H, 1995) |
| "Bromocriptine appears to be an interesting development in the treatment of Parkinson's disease." | 2.64 | [Treatment of parkinsonian syndromes by bromocriptin]. ( Durand, JP; Gautier, JC, 1977) |
| "Amantadine is a putative dopaminergic compound known to be therapeutically effective in idiopathic and postencephalitic Parkinson's disease." | 2.64 | Amantadine versus trihexyphenidyl in the treatment of neuroleptic-induced parkinsonism. ( Fann, WE; Lake, CR, 1976) |
| "There are many causes of parkinsonism such as drug induced parkinsonism, subcortical vascular disease, and multisystem atrophy." | 2.42 | [Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?]. ( Ceballos-Baumann, A, 2003) |
| " Acute dystonias consist of abnormal muscle spasms and postures and usually occur three to five days after antipsychotic therapy begins or the dosage is increased." | 2.40 | Management of acute extrapyramidal effects induced by antipsychotic drugs. ( Holloman, LC; Marder, SR, 1997) |
| "Amantadine is an evidence-based pharmacologic strategy for treating drug-induced parkinsonism and might be an alternative treatment for other DIMDs in select patients." | 1.56 | Revisiting amantadine as a treatment for drug-induced movement disorders. ( Caroff, SN; Jain, R; Morley, JF, 2020) |
| "The mice developed catalepsy after 3 weeks on the LCa/Mg diet." | 1.39 | Combined low calcium and lack magnesium is a risk factor for motor deficit in mice. ( Nakagawasai, O; Nemoto, W; Sato, S; Tadano, T; Tan-no, K; Taniguchi, R; Yamadera, F; Yaoita, F, 2013) |
| "Pretreatment with hemantane (10 mg/kg) and the reference drug amantadine (20 mg/kg) 5 days before MPTP and further administration during 3 weeks after MPTP preserve cognitive function and prevented depressive disturbances in rats." | 1.38 | [Study of hemantane effects in rats on a model of early (premotor) stage of Parkinson's disease]. ( Ivanova, EA; Kapitsa, IG; Nepoklonov, AV; Val'dman, EA; Voronina, TA, 2012) |
| "The diagnosis of patients 2 and 3 was vascular dementia with multiple subcortical ischemic lesions, and single photon emission CTs showed reduced cerebral blood flow in the frontal lobes." | 1.29 | [Improved perseveration with amantadine]. ( Imamura, T; Itoh, H; Itoh, M; Nagasawa, H; Sahara, M; Suzuki, K; Yamadori, A, 1994) |
| " An increase in dosage also had only a transient effect." | 1.27 | Development of tolerance to the therapeutic effect of amantadine on akathisia. ( Barreira, P; Lipinski, JF; Zubenko, GS, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 41 (66.13) | 18.7374 |
| 1990's | 11 (17.74) | 18.2507 |
| 2000's | 4 (6.45) | 29.6817 |
| 2010's | 5 (8.06) | 24.3611 |
| 2020's | 1 (1.61) | 2.80 |
| Authors | Studies |
|---|---|
| Caroff, SN | 1 |
| Jain, R | 1 |
| Morley, JF | 1 |
| Tronci, E | 1 |
| Fidalgo, C | 1 |
| Zianni, E | 1 |
| Collu, M | 1 |
| Stancampiano, R | 1 |
| Morelli, M | 1 |
| Gardoni, F | 1 |
| Carta, M | 1 |
| Cheung, YF | 1 |
| Hui, CH | 1 |
| Chan, JH | 1 |
| Bido, S | 1 |
| Marti, M | 1 |
| Morari, M | 1 |
| Nepoklonov, AV | 1 |
| Kapitsa, IG | 1 |
| Ivanova, EA | 1 |
| Voronina, TA | 1 |
| Val'dman, EA | 1 |
| Taniguchi, R | 1 |
| Nakagawasai, O | 1 |
| Tan-no, K | 1 |
| Yamadera, F | 1 |
| Nemoto, W | 1 |
| Sato, S | 1 |
| Yaoita, F | 1 |
| Tadano, T | 1 |
| Takahashi, H | 1 |
| Shinohara, Y | 1 |
| Ceballos-Baumann, A | 1 |
| Bibbiani, F | 1 |
| Oh, JD | 1 |
| Kielaite, A | 1 |
| Collins, MA | 1 |
| Smith, C | 1 |
| Chase, TN | 2 |
| Borison, RL | 1 |
| Zubenko, GS | 1 |
| Barreira, P | 1 |
| Lipinski, JF | 1 |
| Gómez, EA | 1 |
| Schunk, W | 1 |
| Danielczyk, W | 1 |
| Chevalier, JF | 1 |
| Renier, E | 1 |
| Brion, S | 1 |
| Lechner, H | 1 |
| Bertha, G | 1 |
| Ott, E | 1 |
| Altagracia, M | 2 |
| Rojas, P | 2 |
| Kravzov, J | 1 |
| Rios, C | 2 |
| Silver, H | 1 |
| Geraisy, N | 1 |
| Schwartz, M | 1 |
| Imamura, T | 1 |
| Suzuki, K | 1 |
| Yamadori, A | 1 |
| Sahara, M | 1 |
| Nagasawa, H | 1 |
| Itoh, M | 1 |
| Itoh, H | 1 |
| Edby, K | 1 |
| Larsson, J | 1 |
| Eek, M | 1 |
| von Wendt, L | 1 |
| Ostergård, B | 1 |
| Danysz, W | 1 |
| Parsons, CG | 1 |
| Kornhuber, J | 1 |
| Schmidt, WJ | 1 |
| Quack, G | 1 |
| Holloman, LC | 1 |
| Marder, SR | 1 |
| Blanchet, PJ | 1 |
| Konitsiotis, S | 1 |
| Ahlskog, JE | 1 |
| Scarmeas, N | 1 |
| Eidelberg, D | 1 |
| Frucht, SJ | 1 |
| Scarmato, N | 1 |
| Mindham, RH | 2 |
| Kaumeier, S | 1 |
| Gautier, JC | 1 |
| Durand, JP | 1 |
| Schneider, E | 1 |
| Fischer, PA | 1 |
| Jacobi, P | 1 |
| Fann, WE | 1 |
| Lake, CR | 1 |
| Pacifici, GM | 1 |
| Nardini, M | 1 |
| Ferrari, P | 1 |
| Latini, R | 1 |
| Fieschi, C | 1 |
| Morselli, PL | 1 |
| Gelenberg, AJ | 1 |
| Mandel, MR | 1 |
| Cerone, G | 1 |
| Ruggieri, S | 1 |
| Aloisi, P | 1 |
| Cappenberg, L | 1 |
| Agnoli, A | 1 |
| Miras Portugal, MT | 1 |
| Aunis, D | 1 |
| Mandel, P | 1 |
| Warter, JM | 1 |
| Coquillat, G | 1 |
| Collard, M | 1 |
| Rohmer, F | 1 |
| Kadykov, AS | 1 |
| Dolezalová, B | 1 |
| Vacek, J | 1 |
| Evtushenko, SK | 1 |
| Kandel', EI | 1 |
| Iadgarov, IS | 1 |
| Völler, GW | 1 |
| Schubert, U | 1 |
| Fischer, GJ | 1 |
| Glass, J | 1 |
| Vardi, J | 1 |
| Streifler, M | 1 |
| Godwin-Austen, R | 1 |
| Kravsov, J | 1 |
| Rausch, WD | 1 |
| Schallauer, E | 1 |
| Chan, WW | 1 |
| Riederer, P | 1 |
| Weiser, M | 1 |
| Rabey, JM | 1 |
| Oberman, Z | 1 |
| Scharf, M | 1 |
| Isakov, M | 1 |
| Bar, M | 1 |
| Graff, E | 1 |
| Keepers, GA | 1 |
| Casey, DE | 1 |
| Fayen, M | 1 |
| Goldman, MB | 1 |
| Moulthrop, MA | 1 |
| Luchins, DJ | 1 |
| Lieberman, AN | 1 |
| Rüther, E | 1 |
| Fussmann-Hegewald, M | 1 |
| Eben, E | 1 |
| Kamianov, IM | 1 |
| Kupisk, AG | 1 |
| Katsen, IZ | 1 |
| Rappaport, M | 1 |
| Velkov, VA | 1 |
| Shimomura, SK | 1 |
| Balunov, OA | 1 |
| Bazhin, EF | 1 |
| Morozova, ES | 1 |
| Fedotenkova, TN | 1 |
| Boczán, G | 1 |
| Gaind, R | 1 |
| Anstee, BH | 1 |
| Rimmer, L | 1 |
| Kelly, JT | 1 |
| Zimmermann, RL | 1 |
| Abuzzahab, FS | 1 |
| Schiele, BC | 1 |
| Kiseleva, AM | 1 |
| Zlydnikov, DM | 1 |
| Mazhinskaia, VP | 1 |
| Lebedeva, VK | 1 |
| Zakharova, NG | 1 |
| Cincă, I | 1 |
| Bulandra, R | 1 |
| Serbănesco, A | 1 |
| Ninosu, N | 1 |
| Albert, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Long-term Effects of Amantadine in Parkinsonian's Suffering From Dyskinesia Induced by Levodopa: Study Randomised Double-blind, Placebo - Cessation of a Chronic Prescription. STUDY AMANDYSK.[NCT00632762] | Phase 4 | 80 participants (Anticipated) | Interventional | 2007-11-30 | Completed | ||
| Utility of Amantadine Hydrochloride in the Treatment of Post-traumatic Irritability: A Randomized, Double-Blind, Placebo-Controlled Trial[NCT00627250] | 76 participants (Actual) | Interventional | 2003-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for amantadine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
[Diagnosis and therapy for patients with vascular parkinsonism].
Topics: Akinetic Mutism; Amantadine; Antiparkinson Agents; Cerebral Infarction; Dementia, Vascular; Diagnosi | 2003 |
[Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?].
Topics: Aged; Amantadine; Antiparkinson Agents; Apomorphine; Botulinum Toxins; Catechols; Cholinesterase Inh | 2003 |
Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents--preclinical studies.
Topics: Amantadine; Animals; Antiparkinson Agents; Excitatory Amino Acid Antagonists; Memantine; Parkinson D | 1997 |
Management of acute extrapyramidal effects induced by antipsychotic drugs.
Topics: Adrenergic beta-Antagonists; Akathisia, Drug-Induced; Amantadine; Antipsychotic Agents; Benzodiazepi | 1997 |
Medical treatment of later-stage motor problems of Parkinson disease.
Topics: Amantadine; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; | 1999 |
[Progress in therapy of Parkinsonian syndrome].
Topics: Amantadine; Carboxy-Lyases; Drug Interactions; Drug Therapy, Combination; Humans; Levodopa; Parasymp | 1975 |
Clinical management of acute neuroleptic-induced extrapyramidal syndromes.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Akathisia, Drug-Induced; Amantadine; Antipsychotic Ag | 1986 |
[Therapy and problems of parkinsonism].
Topics: Adult; Aged; Amantadine; Animals; Antidepressive Agents; Apomorphine; Brain Chemistry; Brain Stem; D | 1971 |
10 trials available for amantadine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
Topics: Adult; Amantadine; Antipsychotic Agents; Biperiden; Cross-Over Studies; Double-Blind Method; Dyskine | 1995 |
Assessment of drugs in schizophrenia. Asessment of drug-induced extrapyramidal reactions and of drugs given for their control.
Topics: Amantadine; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as T | 1976 |
[Treatment of parkinsonian syndromes by bromocriptin].
Topics: Aged; Amantadine; Bromocriptine; Clinical Trials as Topic; Drug Evaluation; Ergolines; Female; Human | 1977 |
Amantadine versus trihexyphenidyl in the treatment of neuroleptic-induced parkinsonism.
Topics: Amantadine; Clinical Trials as Topic; Humans; Parkinson Disease, Secondary; Tranquilizing Agents; Tr | 1976 |
Effect of amantadine on drug-induced parkisonism: relationship between plasma levels and effect.
Topics: Adult; Amantadine; Biological Availability; Clinical Trials as Topic; Female; Half-Life; Humans; Mid | 1976 |
[Treatment of Parkinsonian syndrome using amantadine hydrochloride].
Topics: Adult; Aged; Amantadine; Basal Ganglia Diseases; Clinical Trials as Topic; Drug Evaluation; Electrom | 1975 |
Differential memory function with dopaminergic versus anticholinergic treatment of drug-induced extrapyramidal symptoms.
Topics: Adult; Amantadine; Antipsychotic Agents; Cerebral Ventricles; Clinical Trials as Topic; Dilatation, | 1988 |
Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine-induced Parkinsonism.
Topics: Affect; Amantadine; Basal Ganglia Diseases; Clinical Trials as Topic; Evaluation Studies as Topic; F | 1972 |
A double-blind study of amantadine hydrochloride versus benztropine mesylate in drug-induced parkinsonism.
Topics: Administration, Oral; Amantadine; Antiparkinson Agents; Benztropine; Capsules; Chlorpromazine; Clini | 1974 |
[The therapeutic effectiveness of amantadine (midantan) in parkinsonism syndromes].
Topics: Adult; Aged; Amantadine; Chronic Disease; Female; Humans; Male; Middle Aged; Parasympatholytics; Par | 1973 |
44 other studies available for amantadine and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Revisiting amantadine as a treatment for drug-induced movement disorders.
Topics: Amantadine; Antiparkinson Agents; Humans; Parkinson Disease, Secondary | 2020 |
Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesias; Excitatory Amino Aci | 2014 |
Parkinsonism-hyperpyrexia syndrome due to abrupt withdrawal of amantadine.
Topics: Amantadine; Humans; Male; Middle Aged; Neuroleptic Malignant Syndrome; Parkinson Disease, Secondary; | 2011 |
Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Data Interpretation, Statistical; Dyski | 2011 |
[Study of hemantane effects in rats on a model of early (premotor) stage of Parkinson's disease].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adamantane; Amantadine; Animals; Antiparkinson Agents; | 2012 |
Combined low calcium and lack magnesium is a risk factor for motor deficit in mice.
Topics: Amantadine; Animals; Antiparkinson Agents; Benserazide; Bromocriptine; Calcium; Catalepsy; Dopamine | 2013 |
Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Benzazepines; Benzodiazepines; Disease | 2005 |
Amantadine in the management of extrapyramidal side effects.
Topics: Amantadine; Antipsychotic Agents; Basal Ganglia Diseases; Dyskinesia, Drug-Induced; Dystonia; Humans | 1983 |
Development of tolerance to the therapeutic effect of amantadine on akathisia.
Topics: Adult; Akathisia, Drug-Induced; Amantadine; Bipolar Disorder; Drug Tolerance; Female; Haloperidol; H | 1984 |
[Extrapyramidal reactions and neuroleptic malignant syndrome].
Topics: Adult; Amantadine; Basal Ganglia Diseases; Dantrolene; Haloperidol; Humans; Male; Neuroleptic Malign | 1984 |
[New aspects of chronic occupational manganese poisoning].
Topics: Amantadine; Diagnosis, Differential; Humans; Levodopa; Manganese Poisoning; Occupational Diseases; P | 1982 |
[Crises in the course of Parkinson's disease].
Topics: Aged; Amantadine; Bromocriptine; Depression; Female; Humans; Levodopa; Male; Middle Aged; Parkinson | 1980 |
[Edemas and myocloni concerning a patient with Parkinson's disease treated by amantadine (author's transl)].
Topics: Amantadine; Diuretics; Drug Interactions; Drug Therapy, Combination; Edema; Humans; Male; Middle Age | 1980 |
[Current treatment of Parkinsonian syndrome].
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Humans; Levodopa; Parkinson Disease, Secondary | 1980 |
Amantadine enhances dopamine and serotonin turnover in the MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Brain Chemistry; Corpus Striatum; | 1993 |
[Improved perseveration with amantadine].
Topics: Aged; Amantadine; Aphasia; Dementia, Vascular; Dopamine; Encephalitis; Female; Humans; Magnetic Reso | 1994 |
Amantadine treatment of a patient with anoxic brain injury.
Topics: Activities of Daily Living; Adolescent; Amantadine; Antiparkinson Agents; Brain Damage, Chronic; Bra | 1995 |
Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dopamine Ag | 1998 |
Oculogyric-like crises in a 92-year-old woman with vascular Parkinsonism.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Brain; Brain Ischemia; Diagnosis, Differe | 2001 |
[Parkinsonism].
Topics: Amantadine; Arteriosclerosis; Genes, Dominant; Guam; Histamine H1 Antagonists; Humans; Levodopa; Mid | 1978 |
[Sustained levodopa efficacy in parkinsonism. Results of a four-year long-term follow-up study (author's transl)].
Topics: Activities of Daily Living; Aged; Amantadine; Carboxy-Lyases; Dose-Response Relationship, Drug; Drug | 1977 |
Catatonic reactions to high-potency neuroleptic drugs.
Topics: Adolescent; Adult; Amantadine; Catatonia; Dose-Response Relationship, Drug; Female; Fluphenazine; Ha | 1977 |
[Pharmacological study of parkinsonian tremor. II. Role of the dopamine-acetylcholine system].
Topics: Acetylcholine; Aged; Amantadine; Brain; Dopamine; Female; Humans; Male; Middle Aged; Parasympatholyt | 1977 |
[Dopamine beta hydroxylase. Value and limits of its study in neurology].
Topics: Amantadine; Cold Temperature; Dopamine beta-Hydroxylase; Epilepsy; Humans; Levodopa; Movement Disord | 1976 |
[The effectiveness of amantadine (midantan) in the treatment of the parkinsonian syndrome].
Topics: Amantadine; Arteriosclerosis; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Parkinson Di | 1976 |
[Modern antiparkinsonics (L-dopa and amantadine) and presentday psychiatry (author's transl)].
Topics: Amantadine; Humans; Levodopa; Mental Disorders; Parkinson Disease, Secondary; Psychotic Disorders | 1976 |
[Combined treatment of Parkinsonism with levopa, midantan and anticholinergic drugs].
Topics: Acetylcholine; Adult; Aged; Amantadine; Antiparkinson Agents; Cholinesterases; Drug Therapy, Combina | 1976 |
[Catecholamine excretion and treatment of parkinsonism with midantan].
Topics: Adult; Aged; Amantadine; Catecholamines; Dihydroxyphenylalanine; Dopamine; Epinephrine; Female; Huma | 1976 |
On the synchronizing effect of amantadine-1-hydrochlorid (Symmetrel) on pathological EEG-activity.
Topics: Amantadine; Brain; Cortical Synchronization; Electroencephalography; Female; Humans; Middle Aged; Ne | 1975 |
The treatment of parkinsonism.
Topics: Amantadine; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Parkinson Disease, Secondary | 1975 |
Partially protective effect of amantadine in the MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Corpus Striatum; Dopamine; Homova | 1992 |
Effects of L-deprenyl and amantadine in an MPTP-model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Amantadine; Animals; C | 1990 |
Bromocriptine blood levels after the concomitant administration of levodopa, amantadine and biperiden in Parkinson's disease.
Topics: Administration, Oral; Aged; Amantadine; Biperiden; Bromocriptine; Drug Combinations; Female; Humans; | 1990 |
Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Benserazide; Carbidopa; Drug Ther | 1986 |
The effect of amantadine on neuroleptic-induced parkinsonism.
Topics: Adult; Amantadine; Antipsychotic Agents; Butyrophenones; Female; Humans; Male; Middle Aged; Parkinso | 1973 |
[Experience with the use of midantan for treatment and prevention of the neuroleptic syndrome].
Topics: Adult; Amantadine; Antiparkinson Agents; Antipsychotic Agents; Catatonia; Chlorpromazine; Facial Mus | 1973 |
Mental health research at a state hospital. An attempt at a balanced program.
Topics: Amantadine; Attitude of Health Personnel; Auditory Perception; Behavior Therapy; Computers; Conditio | 1968 |
On the effect of amantadine on ATP content and ATPase activity in brain and blood of rats.
Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Amantadine; Animals; Brain; Brain Chemistry; Dise | 1974 |
Parkinsonism.
Topics: Amantadine; Dihydroxyphenylalanine; Histamine H1 Antagonists; Humans; Parasympatholytics; Parkinson | 1972 |
[Use of the Soviet preparation midantan in the treatment of the Parkinsonian syndrome].
Topics: Adult; Aged; Amantadine; Bipolar Disorder; Depressive Disorder, Major; Female; Humans; Male; Middle | 1974 |
Effect of amantadine (Viregyt-K) on extrapyramidal symptoms of parkinsonian patients.
Topics: Adult; Aged; Amantadine; Basal Ganglia Diseases; Drug Administration Schedule; Extrapyramidal Tracts | 1974 |
[Current medical treatment of Parkinsonian syndromes].
Topics: Adult; Age Factors; Aged; Amantadine; Antiparkinson Agents; Dihydroxyphenylalanine; Drug Combination | 1973 |
Treatment for Parkinsonism, other than levodopa.
Topics: Amantadine; Humans; Parasympatholytics; Parkinson Disease; Parkinson Disease, Secondary | 1972 |
Differentiation of tardive dyskinesias and drug-induced Parkinsonism.
Topics: Amantadine; Diagnosis, Differential; Dihydroxyphenylalanine; Humans; Hyperkinesis; Movement Disorder | 1971 |